Lantheus announces collaboration with NIA-sponsored study called CLARiTI

Lantheus Holdings earlier today announced a collaboration agreement with a National Institute on Aging-sponsored study called the Consortium for Clarity in ADRD Research Through Imaging, or CLARiTI. “This agreement enables the consortium to use MK-6240, Lantheus’ clinical-stage F18-labeled Positron Emission Tomography imaging agent, in its investigation of Alzheimer’s disease and related dementias. MK-6240 targets aggregated tau protein in the form of neurofibrillary tangles, which are a hallmark of several neurodegenerative diseases, including Alzheimer’s disease. The CLARiTI study will involve all 37 Alzheimer’s Disease Research Centers in the United States which will recruit 2,000 subjects and collect their imaging and blood-based biomarker data to generate etiologic profiles for cases of mixed dementia,” the company stated. “MK-6240 is poised to play a pivotal role in propelling Alzheimer’s diagnosis and treatment research to new heights. This agreement aligns with Lantheus’ purpose to actively cultivate collaborations that empower researchers worldwide with essential tools to accelerate clinical research and development of therapies. In an era defined by an unprecedented number of Alzheimer’s diagnoses, the CLARiTI study represents a significant milestone in Alzheimer’s research, with the potential to change the trajectory of this degenerative disease,” said Jean-Claude Provost, MD, Chief Medical Officer, Lantheus.